Literature DB >> 10922363

Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis.

T Tanioka1, Y Nakatani, N Semmyo, M Murakami, I Kudo.   

Abstract

Here we report the molecular identification of cytosolic glutathione (GSH)-dependent prostaglandin (PG) E(2) synthase (cPGES), a terminal enzyme of the cyclooxygenase (COX)-1-mediated PGE(2) biosynthetic pathway. GSH-dependent PGES activity in the cytosol of rat brains, but not of other tissues, increased 3-fold after lipopolysaccharide (LPS) challenge. Peptide microsequencing of purified enzyme revealed that it was identical to p23, which is reportedly the weakly bound component of the steroid hormone receptor/hsp90 complex. Recombinant p23 expressed in Escherichia coli and 293 cells exhibited all the features of PGES activity detected in rat brain cytosol. A tyrosine residue near the N terminus (Tyr(9)), which is known to be critical for the activity of cytosolic GSH S-transferases, was essential for PGES activity. The expression of cPGES/p23 was constitutive and was unaltered by proinflammatory stimuli in various cells and tissues, except that it was increased significantly in rat brain after LPS treatment. cPGES/p23 was functionally linked with COX-1 in marked preference to COX-2 to produce PGE(2) from exogenous and endogenous arachidonic acid, the latter being supplied by cytosolic phospholipase A(2) in the immediate response. Thus, functional coupling between COX-1 and cPGES/p23 may contribute to production of the PGE(2) that plays a role in maintenance of tissue homeostasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922363     DOI: 10.1074/jbc.M003504200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  160 in total

Review 1.  Why there are two cyclooxygenase isozymes.

Authors:  W L Smith; R Langenbach
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  Regulated formation of eicosanoids.

Authors:  F A Fitzpatrick; R Soberman
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Role of prostaglandins in fibroblast activation and fibrosis.

Authors:  Richard Stratton; Xu Shiwen
Journal:  J Cell Commun Signal       Date:  2010-03-26       Impact factor: 5.782

4.  Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.

Authors:  Hui-Hua Chang; Zuohe Song; Lee Wisner; Tina Tripp; Vijay Gokhale; Emmanuelle J Meuillet
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

Review 5.  p23, a simple protein with complex activities.

Authors:  Sara J Felts; David O Toft
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

Review 6.  Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics.

Authors:  Charles N Serhan; Bruce Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

Review 7.  The organization and consequences of eicosanoid signaling.

Authors:  Roy J Soberman; Peter Christmas
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 8.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

9.  Characterization of plant p23-like proteins for their co-chaperone activities.

Authors:  Zhongming Zhang; William Sullivan; Sara J Felts; Bishun D Prasad; David O Toft; Priti Krishna
Journal:  Cell Stress Chaperones       Date:  2010-03-28       Impact factor: 3.667

10.  Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux.

Authors:  T J Jang; S K Min; J D Bae; K H Jung; J I Lee; J R Kim; W S Ahn
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.